>>Signaling Pathways>> Neuroscience>> Ophthalmology>>17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide

17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide (Synonyms: 17phenyl trinor PGF2α cyclopropyl methyl amide)

Catalog No.GC41970

Prostaglandin F2α (PGF2α) activates the FP receptor, promoting smooth muscle contraction and luteolysis.

Products are for research use only. Not for human use. We do not sell to patients.

17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide Chemical Structure

Cas No.: 1138395-10-4

Size 가격 재고 수량
1mg
US$101.00
재고 있음
5mg
US$455.00
재고 있음
10mg
US$809.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Prostaglandin F2α (PGF2α) activates the FP receptor, promoting smooth muscle contraction and luteolysis. 17-phenyl trinor PGF2α binds the FP receptor on ovine luteal cells with a relative potency of 756% compared to that of PGF2α. It is produced in vivo by the hydrolysis of 17-phenyl trinor PGF2α ethyl amide. 17-phenyl trinor PGF2α ethyl amide is used to reduce intraocular pressure related to glaucoma. 17-phenyl trinor PGF2α cyclopropyl methyl amide is a lipophilic analog of 17-phenyl trinor PGF2α. Amides of PGs may serve as prodrugs, as they are hydrolyzed in certain tissues to generate the bioactive free acid.

리뷰

Review for 17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 17-phenyl trinor Prostaglandin F2α cyclopropyl methyl amide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.